{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T12:46:23Z","timestamp":1784119583305,"version":"3.55.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.clinthera.2024.08.011","type":"journal-article","created":{"date-parts":[[2024,10,5]],"date-time":"2024-10-05T04:21:42Z","timestamp":1728102102000},"page":"773-777","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Efficacy and Safety of Aflibercept and Ranibizumab in the Treatment of Retinopathy of Prematurity"],"prefix":"10.1016","volume":"46","author":[{"given":"Tiantian","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingfei","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shouhui","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8301-9529","authenticated-orcid":false,"given":"Xiuyong","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2024.08.011_bib0001","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/j.ophtha.2022.06.042","article-title":"A network meta-analysis of retreatment rates following bevacizumab, ranibizumab, aflibercept, and laser for retinopathy of prematurity","volume":"129","author":"Chang","year":"2022","journal-title":"Ophthalmology"},{"key":"10.1016\/j.clinthera.2024.08.011_bib0002","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.ajo.2020.05.025","article-title":"Retinopathy of prematurity: evolving treatment with anti-vascular endothelial growth factor","volume":"218","author":"Hartnett","year":"2020","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.clinthera.2024.08.011_bib0003","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1167\/iovs.16-20680","article-title":"Recurrence of retinopathy of prematurity after intravitreal ranibizumab monotherapy: timing and risk factors","volume":"58","author":"Lyu","year":"2017","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.clinthera.2024.08.011_bib0004","doi-asserted-by":"crossref","first-page":"e1004","DOI":"10.1111\/aos.14460","article-title":"Comparison of the effectiveness of conbercept and ranibizumab treatment for retinopathy of prematurity","volume":"98","author":"Cheng","year":"2020","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.clinthera.2024.08.011_bib0005","first-page":"933","article-title":"Guidelines for screening retinopathy of prematurity in China (2014)","volume":"50","year":"2014","journal-title":"Chin J Ophthalmol"},{"key":"10.1016\/j.clinthera.2024.08.011_bib0006","doi-asserted-by":"crossref","first-page":"eAO6692","DOI":"10.31744\/einstein_journal\/2022AO6692","article-title":"Evaluation of the prematurity retinopathy and other eye changes in the newborn","volume":"20","author":"Dos Santos Martins","year":"2022","journal-title":"Einstein (Sao Paulo)"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2024.08.011_bib0007","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/pr.2013.205","article-title":"Preterm-associated visual impairment and estimates of retinopathy of prematurity at regional and global levels for 2010","volume":"74","author":"Blencowe","year":"2013","journal-title":"Pediatr Res"},{"key":"10.1016\/j.clinthera.2024.08.011_bib0008","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1111\/ppe.12810","article-title":"Incidence of retinopathy of prematurity treatment in extremely preterm infants in China","volume":"36","author":"Dai","year":"2022","journal-title":"Paediatr Perinat Epidemiol"},{"key":"10.1016\/j.clinthera.2024.08.011_bib0009","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/S0140-6736(19)31344-3","article-title":"Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): an open-label randomised controlled trial","volume":"394","author":"Stahl","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2024.08.011_bib0010","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/nrd3700","article-title":"Aflibercept","volume":"11","author":"Stewart","year":"2012","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.clinthera.2024.08.011_bib0012","doi-asserted-by":"crossref","first-page":"e51","DOI":"10.1016\/j.ophtha.2021.05.031","article-title":"International classification of retinopathy of prematurity, third edition","volume":"128","author":"Chiang Michael","year":"2021","journal-title":"Ophthalmology"},{"key":"10.1016\/j.clinthera.2024.08.011_bib0014","first-page":"836","article-title":"Fundus Group of Ophthalmology Branch of Chinese Medical Association. Expert consensus on intravitreal injection of antivascular endothelial growth factor therapy for retinopathy of prematurity","volume":"37","year":"2021","journal-title":"Chin J Fundus Dis"},{"key":"10.1016\/j.clinthera.2024.08.011_bib0015","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1080\/14740338.2020.1826927","article-title":"A safety review of drugs used for the treatment of retinopathy of prematurity","volume":"19","author":"Filippi","year":"2020","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.clinthera.2024.08.011_bib0016","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1097\/ICU.0000000000000786","article-title":"Description and management of retinopathy of prematurity reactivation after intravitreal antivascular endothelial growth factor therapy","volume":"32","author":"Valikodath Nita","year":"2021","journal-title":"Curr Opin Ophthalmol"},{"key":"10.1016\/j.clinthera.2024.08.011_bib0017","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1097\/IAE.0000000000001763","article-title":"Short-term outcomes after intravitreal injections of conbercept versus ranibizumab for the treatment of retinopathy of prematurity","volume":"38","author":"Jin","year":"2018","journal-title":"Retina"},{"key":"10.1016\/j.clinthera.2024.08.011_bib0018","article-title":"Incomplete response to Anti-VEGF therapy in neovascular AMD: Exploring disease mechanisms and therapeutic opportunities","volume":"82","author":"Mettu Priyatham","year":"2021","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.clinthera.2024.08.011_bib0019","doi-asserted-by":"crossref","first-page":"afab262","DOI":"10.1093\/ageing\/afab262","article-title":"Ten-year mortality and long-term visual acuity outcomes in patients with exudative age-related macular degeneration treated with intravitreal anti-vascular endothelial growth factor injections","volume":"51","author":"Young","year":"2022","journal-title":"Age Ageing"},{"key":"10.1016\/j.clinthera.2024.08.011_bib0020","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/s41598-021-04221-8","article-title":"Oxygen care and treatment of retinopathy of prematurity in ocular and neurological prognosis","volume":"12","author":"Kang","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.clinthera.2024.08.011_bib0026","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s00417-018-4168-5","article-title":"Comparison of clinical outcomes of intravitreal ranibizumab and aflibercept treatment for retinopathy of prematurity","volume":"257","author":"Sukgen","year":"2019","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.clinthera.2024.08.011_bib0021","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1097\/IAE.0000000000001862","article-title":"Intravitreal aflibercept and ranibizumab injections for type 3 neovascularization","volume":"38","author":"Cho","year":"2018","journal-title":"Retina"},{"key":"10.1016\/j.clinthera.2024.08.011_bib0022","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s00417-018-4168-5","article-title":"Comparison of clinical outcomes of intravitreal ranibizumab and aflibercept treatment for retinopathy of prematurity","volume":"257","author":"Sukgen","year":"2019","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.clinthera.2024.08.011_bib0023","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1136\/bjophthalmol-2020-318026","article-title":"Comparison of clinical outcomes of conbercept versus ranibizumab treatment for retinopathy of prematurity: a multicentral prospective randomised controlled trial","volume":"106","author":"Wu","year":"2022","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.clinthera.2024.08.011_bib0024","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/S2352-4642(21)00195-4","article-title":"2-year outcomes of ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW extension study): prospective follow-up of an open label, randomised controlled trial","volume":"5","author":"Marlow","year":"2021","journal-title":"Lancet Child Adolesc Health"},{"key":"10.1016\/j.clinthera.2024.08.011_bib0025","article-title":"Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity","volume":"1","author":"Sankar","year":"2018","journal-title":"Cochrane Database Syst Rev"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291824002248?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291824002248?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T02:50:46Z","timestamp":1730343046000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291824002248"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":24,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S0149291824002248"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2024.08.011","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and Safety of Aflibercept and Ranibizumab in the Treatment of Retinopathy of Prematurity","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2024.08.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}